First Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast Cancer

(MedPage Today) — BERLIN — For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall survival (OS) in high-risk early breast cancer, data reported here showed.
Patients who received…

Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118016

Author :

Publish date : 2025-10-18 17:26:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

First Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast Cancer

Durvalumab Plus FLOT Ups Survival in Early Upper-GI Cancer

AI and Healthcare; New Drug for Lupus

Related Posts

Doctors Have a Front-Row Seat to the Caregiver Crisis

Novel Alzheimer’s Pill May Slow Decline in Some High-Risk Patients

Standard-of-Care Treatment for Rheumatoid Arthritis Lags for Minority Groups

Cardiologist Heads New ACIP; Distal Access Catheter Recall; Another Lipid Marker?

Delaying Hep B Vaccine in Infants Carries Significant Risks, Report Warns

Interatrial Shunt to Go Before FDA Panel for Heart Failure Indication

Doctors Have a Front-Row Seat to the Caregiver Crisis

Novel Alzheimer’s Pill May Slow Decline in Some High-Risk Patients

Standard-of-Care Treatment for Rheumatoid Arthritis Lags for Minority Groups

Cardiologist Heads New ACIP; Distal Access Catheter Recall; Another Lipid Marker?

Delaying Hep B Vaccine in Infants Carries Significant Risks, Report Warns

Interatrial Shunt to Go Before FDA Panel for Heart Failure Indication

Polypharmacy Is a Real Issue. Dismantling Public Health Won’t Fix It.

Future Directions in DLBCL: Innovations in the Frontline and Relapsed Settings

Categories

Archives